Ipilimumab
Yervoy (ipilimumab) is an antibody pharmaceutical. Ipilimumab was first approved as Yervoy on 2011-03-25. It is used to treat melanoma in the USA. It has been approved in Europe to treat colorectal neoplasms, malignant mesothelioma, melanoma, non-small-cell lung carcinoma, and renal cell carcinoma. The pharmaceutical is active against cytotoxic T-lymphocyte protein 4.
| Trade Name | Yervoy |
|---|---|
| Common Name | Ipilimumab |
| Indication | colorectal neoplasms, malignant mesothelioma, melanoma, non-small-cell lung carcinoma, renal cell carcinoma |
| Drug Class | Monoclonal antibodies |
